22157.jpg
Molecular Diagnostics for Infectious Disease Markets, 2025 - C19Dx Demand Sweeps Over the Globe
January 29, 2021 04:13 ET | Research and Markets
Dublin, Jan. 29, 2021 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics for Infectious Disease By Syndrome, Plex, Place and by Country. With COVID-19 Impact & Forecasting/Analysis, and Executive...
22157.jpg
The Global Market for Molecular Diagnostics Infectious Disease 2021-2025
November 24, 2020 17:23 ET | Research and Markets
Dublin, Nov. 24, 2020 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics for Infectious Disease By Syndrome, Plex, Place and by Country. With COVID-19 Impact & Forecasting/Analysis, and Executive...
ContraFect_LOGO_Web.jpg
ContraFect Announces Plan for a Single Phase 3 Superiority Design Study of Exebacase Following Successful End-of-Phase 2 Meeting with FDA
October 02, 2019 07:00 ET | ContraFect Corporation
Primary Endpoint of Clinical Response at Day 14 in Patients with Methicillin-Resistant Staph aureus (MRSA) Bacteremia, including Right-Sided Endocarditis Study Initiation Planned by Year-End 2019 ...
ContraFect_LOGO_Web.jpg
ContraFect Awarded $7.2 Million USAMRDC Grant to Support the Advancement of Lysin Candidate CF-296
June 06, 2019 07:00 ET | ContraFect Corporation
YONKERS, N.Y., June 06, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for...
ContraFect_LOGO_Web.jpg
ContraFect Announces Presentation at the International Society of Cardiovascular Infectious Diseases Symposium
June 03, 2019 07:00 ET | ContraFect Corporation
YONKERS, N.Y., June 03, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for...
ContraFect_LOGO_Web.jpg
ContraFect Announces Publication of Paper on Recent Exebacase Data in Antimicrobial Agents and Chemotherapy Journal
May 31, 2019 07:00 ET | ContraFect Corporation
YONKERS, N.Y., May 31, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for...
ContraFect_LOGO_Web.jpg
ContraFect to Present at Cantor Antibiotics Summit
January 11, 2018 07:00 ET | ContraFect Corporation
YONKERS, N.Y., Jan. 11, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect_LOGO_Web.jpg
ContraFect to Present at 10th Annual Biotech Showcase
January 03, 2018 07:00 ET | ContraFect Corporation
YONKERS, N.Y., Jan. 03, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect_LOGO_Web.jpg
ContraFect to Present at the 29th Annual Piper Jaffray Healthcare Conference
November 15, 2017 07:00 ET | ContraFect Corporation
YONKERS, N.Y., Nov. 15, 2017 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect_LOGO_Web.jpg
ContraFect to Present at the 2nd Annual Superdrugs and Superbugs USA Conference
November 10, 2017 07:00 ET | ContraFect Corporation
YONKERS, N.Y., Nov. 10, 2017 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...